<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2013.1417</article-id>
<article-id pub-id-type="publisher-id">mmr-07-06-1865</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Hydrogen sulfide prevents H<sub>2</sub>O<sub>2</sub>-induced senescence in human umbilical vein endothelial cells through SIRT1 activation</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>SUO</surname><given-names>RONG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>ZHAO</surname><given-names>ZHAN-ZHI</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>TANG</surname><given-names>ZHI-HAN</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>REN</surname><given-names>ZHONG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>XING</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>LU-SHAN</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>ZUO</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>TANG</surname><given-names>CHAO-KE</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>WEI</surname><given-names>DANG-HENG</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>JIANG</surname><given-names>ZHI-SHENG</given-names></name><xref ref-type="corresp" rid="c1-mmr-07-06-1865"/></contrib>
<aff id="af1-mmr-07-06-1865">Institute of Cardiovascular Disease and Key Laboratory for Arteriosclerology of Hunan Province, University of South China, Hengyang, Hunan 421001, P.R. China</aff></contrib-group>
<author-notes>
<corresp id="c1-mmr-07-06-1865">Correspondence to: Professor Zhi-Sheng Jiang, Institute of Cardiovascular Disease and Key Laboratory for Arteriosclerology of Hunan Province, University of South China, No. 28 Changsheng West Road, Hengyang 421001, Hunan, P.R. China, E-mail: <email>zsjiang2005@163.com</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>6</month>
<year>2013</year></pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>04</month>
<year>2013</year></pub-date>
<volume>7</volume>
<issue>6</issue>
<fpage>1865</fpage>
<lpage>1870</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>01</month>
<year>2013</year></date>
<date date-type="accepted">
<day>20</day>
<month>03</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013, Spandidos Publications</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>The aim of the present study was to investigate the attenuation of endothelial cell senescence by H<sub>2</sub>S and to explore the mechanisms underlying the anti-aging effects of H<sub>2</sub>S. Senescence was induced in human umbilical vein endothelial cells (HUVECs) by incubation in 25 &#x003BC;mol/l H<sub>2</sub>O<sub>2</sub> for 1 h. Senescence-associated &#x003B2;-galactosidase (SA-&#x003B2;-gal) activity was examined to determine the effects of H<sub>2</sub>S on senescent HUVECs. The results indicated that SA-&#x003B2;-gal activity in the H<sub>2</sub>O<sub>2</sub>-treated HUVECs was 11.2&#x000B1;1.06&#x00025;, which was attenuated in the NaHS group. Pretreatment with nicotinamide (NAM), a sirtuin 1 (SIRT1) inhibitor, inhibited the reduction in senescence associated with H<sub>2</sub>S. Immunoblot analyses revealed that SIRT1 levels in senescent HUVECs treated with NaHS (60 &#x003BC;M) were indistinguishable from controls; however, analyses of SIRT1 activity indicated that SIRT1 enzyme activity was enhanced. In addition, we found that H<sub>2</sub>S improves the function of senescent HUVECs. The present study demonstrated that H<sub>2</sub>S protects against HUVEC senescence, potentially through modulation of SIRT1 activity. Furthermore, this study establishes a novel endothelial protective effect of H<sub>2</sub>S.</p></abstract>
<kwd-group>
<kwd>sirtuin 1</kwd>
<kwd>oxidative stress</kwd>
<kwd>cardiovascular</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>During aging, a number of physiological functions are altered and the cessation of cell division is accompanied by specific changes in cell function, morphology and gene expression. These changes may contribute to age-associated diseases, including hypertension, chronic coronary disease and diabetes (<xref rid="b1-mmr-07-06-1865" ref-type="bibr">1</xref>). Vascular endothelial cells (VEC) are highly specialized and active cells exhibiting antithrombotic and anti-inflammatory properties. These cells are critically involved in the maintenance of vascular homeostasis by regulating vascular tone and integrity, as well as remodeling processes (<xref rid="b2-mmr-07-06-1865" ref-type="bibr">2</xref>). Vascular cell senescence, which accompanies aging, promotes endothelial cell dysfunction (<xref rid="b3-mmr-07-06-1865" ref-type="bibr">3</xref>) and is associated with increased vascular risk (<xref rid="b4-mmr-07-06-1865" ref-type="bibr">4</xref>). Pathological states, including those observed in oxidative stress conditions, invoke irreversible growth arrest <italic>in vitro</italic> within a few days, a term referred to as stress-induced premature senescence (SIPS) (<xref rid="b5-mmr-07-06-1865" ref-type="bibr">5</xref>,<xref rid="b6-mmr-07-06-1865" ref-type="bibr">6</xref>). Previous evidence suggests that premature senescence of endothelial cells may lead to endothelial dysfunction and atherogenesis (<xref rid="b3-mmr-07-06-1865" ref-type="bibr">3</xref>).</p>
<p>Hydrogen sulfide (H<sub>2</sub>S) has attracted considerable interest as an endogenous gaseous mediator and potential pharmacological/therapeutic tool. It is endogenously generated from cysteine, in reactions catalyzed by cystathionine &#x003B2;-synthase (CBS) or cystathionine &#x003B3;-lyase (CSE) (<xref rid="b7-mmr-07-06-1865" ref-type="bibr">7</xref>). Studies in various species, including humans have demonstrated that H<sub>2</sub>S is involved in diverse physiological and pathophysiological processes, including regulation of blood pressure (<xref rid="b8-mmr-07-06-1865" ref-type="bibr">8</xref>), inflammation (<xref rid="b9-mmr-07-06-1865" ref-type="bibr">9</xref>) and metabolic disorders (<xref rid="b10-mmr-07-06-1865" ref-type="bibr">10</xref>). The beneficial effects of H<sub>2</sub>S may be mediated through its antioxidant effects. H<sub>2</sub>S is a potent inhibitor of O<sub>2</sub><sup>-</sup> formation and gp91phox expression induced by TNF-&#x003B1; in pulmonary artery endothelial cells (PAECs) (<xref rid="b11-mmr-07-06-1865" ref-type="bibr">11</xref>). Furthermore, H<sub>2</sub>S protects endothelial cells against oxidized low-density lipoprotein (LDL) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-mediated cell cytotoxicity (<xref rid="b12-mmr-07-06-1865" ref-type="bibr">12</xref>). H<sub>2</sub>S also appears to be a potent scavenger of oxygen-derived free radicals (<xref rid="b13-mmr-07-06-1865" ref-type="bibr">13</xref>), which may contribute to the protective role of NaHS against the toxicity of H<sub>2</sub>O<sub>2</sub><italic>in vitro</italic> and <italic>in vivo</italic>(<xref rid="b14-mmr-07-06-1865" ref-type="bibr">14</xref>). Findings of a previous study from our laboratory indicated that the endogenous CSE/H<sub>2</sub>S system is downregulated in adipose tissues during aging (<xref rid="b15-mmr-07-06-1865" ref-type="bibr">15</xref>). Another study reported that thermotolerance and lifespan of <italic>Caenorhabditis elegans</italic> (<italic>C. elegans</italic>) was increased when exposed to H<sub>2</sub>S, which was mediated by SIR-2.1 activity (<xref rid="b16-mmr-07-06-1865" ref-type="bibr">16</xref>).</p>
<p>SIR-2.1 is a <italic>C. elegans</italic> ortholog to sirtuin 1 (SIRT1), which is commonly known as nicotinamide adenine dinucleotide (NAD<sup>&#x0002B;</sup>)-dependent class III histone deacetylase. This enzyme has been shown to modulate lifespan in yeast, worms, flies and mice. A mammalian SIRT1 homolog, silent information regulator-2 (Sir2), is highly conserved in organisms ranging from archaea to humans and it has been shown to regulate cell cycle, senescence, apoptosis and metabolism by interacting with a number of molecules, including p53 (<xref rid="b17-mmr-07-06-1865" ref-type="bibr">17</xref>) and Foxo1 (<xref rid="b18-mmr-07-06-1865" ref-type="bibr">18</xref>). A previous study demonstrated that SIRT1 inhibition induces premature senescence-like growth arrest in human cancer cells (<xref rid="b19-mmr-07-06-1865" ref-type="bibr">19</xref>). The aim of the present study was to investigate the effects of H<sub>2</sub>S, using the donor NaHS, on the inhibition of H<sub>2</sub>O<sub>2</sub>-induced senescence in human umbilical vein endothelial cells (HUVECs) and the role of SIRT1 in this process.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Materials</title>
<p>3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), collagenase II, sodium hydrosulfide (NaHS) and DL-propargylglycine (PPG) were purchased from Sigma Aldrich (Zwijndrecht, Netherlands). Endothelial cell growth supplement (ECGS) was purchased from ScienCell Research Laboratories, Inc. (Carlsbad, CA, USA). p21 and SIRT1 antibodies and the Senescence &#x003B2;-Galactosidase Staining Kit were purchased from the Beyotime Institute of Biotechnology (Shanghai, China). Luminol reagent and polyvinylidene fluoride (PVDF) membranes were purchased from Millipore (Billerica, MA, USA).</p></sec>
<sec>
<title>Cell cultures</title>
<p>HUVECs were isolated from newborn umbilical cords and cultured in M199 (Gibco, Grand Island, NY, USA) supplemented with 20&#x00025; fetal bovine serum (FBS) and 2&#x00025; EGCS at 37&#x000B0;C under 5&#x00025; CO<sub>2</sub> in a humidified atmosphere. Cells were used during passages two or three.</p></sec>
<sec>
<title>Immunohistochemistry</title>
<p>Immunohistochemical staining of the HUVECs for factor VIII-like antigen (fVIII-AGN) was performed on confluent cultures grown in 35-mm dishes. The media was aspirated and the cells were washed with phosphate-buffered saline (PBS) prior to fixing in bovine serum albumin (BSA) for 15 min at room temperature. The cells were washed again with PBS and incubated with a 1:40 (v/v) dilution of horseradish peroxidase (HRP)-conjugated rabbit anti-human fVIII:AGN (Bioss Inc., Woburn, MA, USA) for 45 min. The dishes were washed in triplicate with PBS, rinsed briefly with distilled water and mounted with buffered glycerol on glass cover slips. HRP-bound primary antibody was detected and observed using 3,3&#x02032;-diaminobenzidine (DAB). Smooth muscle cells served as negative controls.</p></sec>
<sec>
<title>Senescence-associated &#x003B2;-galactosidase (SA-&#x003B2;-gal) staining</title>
<p>SA-&#x003B2;-gal activity was measured using a senescence cell staining kit. HUVECs were pretreated with various concentrations of NaHS, 5 mM NAM or a combination of NaHS and NAM for 48 h. The cells were then placed in media supplemented with 25 &#x003BC;M H<sub>2</sub>O<sub>2</sub> for 1 h. The media were then replaced with normal medium and incubated for an additional 72 h. The cells were washed twice with PBS and the HUVECs were fixed and stained for SA-&#x003B2;-gal activity using the Senescence &#x003B2;-Galactosidase Staining Kit. The cells were then incubated at 37&#x000B0;C for 16 h and SA-&#x003B2;-gal-positive cells were observed using microscopy, which included counting &gt;400 cells in three independent fields. The percentage of SA-&#x003B2;-gal-positive cells was determined by counting the number of green cells within a sample (<xref rid="b20-mmr-07-06-1865" ref-type="bibr">20</xref>).</p></sec>
<sec>
<title>Cell cycle assay</title>
<p>To determine the effect of H<sub>2</sub>O<sub>2</sub> on cell cycle progression, HUVECs were grown for 1 h with or without 25 &#x003BC;mol/l H<sub>2</sub>O<sub>2</sub>. Cells were collected using trypsinization and centrifugation for 5 min at 300 &#x000D7; g and were fixed with 70&#x00025; ethanol at 4&#x000B0;C overnight. Cells were centrifuged to remove alcohol, stained with 50 mmol/l propidium iodide and washed twice with cold PBS. HUVECs were subjected to flow cytometric analyses with FACSCalibur and CellQuest software (BD Biosciences, Franklin Lakes, NJ, USA). Cell cycles were analyzed and the proportion of cells in the G<sub>0</sub>/G<sub>1</sub>, S and G<sub>2</sub>/M phases was recorded.</p></sec>
<sec>
<title>Immunoblot analyses</title>
<p>Protein extracts were prepared using the mammalian cell extraction kit following the manufacturer&#x02019;s instructions. Protein concentrations were determined using a BCA Protein Assay kit (Pierce, Biotechnology, Inc., Rockford, IL, USA). Extracted proteins were treated with 5&#x00025; sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, then heated at 100&#x000B0;C for 10 min and separated using electrophoresis on a 10&#x00025; SDS-polyacrylamide gel. Equal amounts of protein were separated using SDS-PAGE and then transferred to PVDF membranes. The membranes were incubated in a blocking buffer containing BSA (1&#x00025;) and Tween-20 (0.1&#x00025;, v/v) in Tris-buffered saline with Tween-20 (TBST) at room temperature for 2 h, and inoculated overnight at 4&#x000B0;C with the primary antibodies, anti-human &#x003B2;-actin (1:500) and anti-human SIRT1 (1:300). The membranes were then inoculated with goat anti-rabbit (1:3,000) and goat anti-mouse (1:1,500) HRP-conjugated secondary antibodies at room temperature for 2 h. Each membrane was developed using enhanced chemiluminescence detection and quantified by densitometry.</p></sec>
<sec>
<title>Enzymatic activity assay</title>
<p>A SIRT1 enzyme activity assay was performed to determine the effect of H<sub>2</sub>S on activity using a commercially available kit (Genmed, Plymouth, MN, USA). After preparing cell lysates, the SIRT1 activity assay was performed in a 96-well plate according to the manufacturer&#x02019;s instructions. The reaction product emitted fluorescence, which was detected using an excitation wavelength of 350 nm and an emission wavelength of 405 nm.</p></sec>
<sec>
<title>Cell proliferation assay</title>
<p>Proliferation of HUVECs was determined using an MTT assay (<xref rid="b21-mmr-07-06-1865" ref-type="bibr">21</xref>). Forty-eight hours after cell seeding, the media were removed and 210 &#x003BC;l fresh culture media and 50 &#x003BC;l MTT solution (5 mg/ml in PBS) were added to each well, followed by incubation for 2 h at 37&#x000B0;C in a 5&#x00025; CO<sub>2</sub> atmosphere. The cells were cultured for 4 h at 37&#x000B0;C in a 5&#x00025; CO<sub>2</sub> atmosphere and the optical density of the solution was evaluated using a microplate spectrophotometer at 595 nm.</p></sec>
<sec>
<title>Cell scratch assay</title>
<p>To determine the functional consequences of senescence induced by H<sub>2</sub>O<sub>2</sub>, the <italic>in vitro</italic> scratch injury model was used. Cells were seeded in a 96-well plate and treated 24 h after seeding. Twenty-four hours after treatment, a thin-line, devoid of cells, was made by scratching the culture plate bottom with a 10 &#x003BC;l pipette tip. Following scratching, the wells were washed with PBS and fresh media were added. Two images were captured per well; the width of the scratch was measured at four points per image with Image-Pro Plus and the means were calculated.</p></sec>
<sec>
<title>Statistical analyses</title>
<p>Results are expressed as mean &#x000B1; standard error of the mean (SEM) or mean &#x000B1; standard deviation (SD). Differences between groups were evaluated using analysis of variance, Dunnett&#x02019;s test or the least significant difference t-test. P&lt;0.05 was considered to indicate a statistically significant difference.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Establishing a senescence model in HUVECs</title>
<p>To investigate the effect of H<sub>2</sub>S on HUVEC senescence, we utilized an established senescence model, which involved incubating the cells with 25 &#x003BC;mol/l H<sub>2</sub>O<sub>2</sub> for 1 h (<xref rid="b22-mmr-07-06-1865" ref-type="bibr">22</xref>). Using light microscopy, we confirmed the presence of senescent HUVECs, which exhibited increased cell size and cytoplasmic granularity (<xref rid="f1-mmr-07-06-1865" ref-type="fig">Fig. 1A</xref>). The number of SA-&#x003B2;-gal-positive cells (<xref rid="f1-mmr-07-06-1865" ref-type="fig">Fig. 1A</xref>) and the proportion of HUVECs in the G<sub>0</sub>/G<sub>1</sub> phase (<xref rid="f1-mmr-07-06-1865" ref-type="fig">Fig. 1C</xref>) were increased, indicating the presence of senescent cells. In order to confirm our results, we investigated p21 levels, which were increased in senescence (<xref rid="b23-mmr-07-06-1865" ref-type="bibr">23</xref>). Immunoblot analyses indicated that p21 levels were increased in HUVECs treated with H<sub>2</sub>O<sub>2</sub> (<xref rid="f1-mmr-07-06-1865" ref-type="fig">Fig. 1B</xref>). Collectively, these results indicate that the low concentration of H<sub>2</sub>O<sub>2</sub> used in our study induced cell senescence.</p></sec>
<sec>
<title>H<sub>2</sub>S protects against HUVEC senescence</title>
<p>SA-&#x003B2;-gal is a well-accepted biochemical marker of cell senescence (<xref rid="b24-mmr-07-06-1865" ref-type="bibr">24</xref>). Examination of SA-&#x003B2;-gal activity in HUVECs treated with H<sub>2</sub>O<sub>2</sub> (25 &#x003BC;M) revealed a significant increase in SA-&#x003B2;-gal-positive cells, which reached 11.2&#x000B1;1.06&#x00025; (<xref rid="f1-mmr-07-06-1865" ref-type="fig">Fig. 1A</xref>). However, increases in SA-&#x003B2;-gal-positive cells were significantly attenuated in the NaHS (60 &#x003BC;M) group (<xref rid="f2-mmr-07-06-1865" ref-type="fig">Fig. 2A and B</xref>).</p>
<p>Progression through the cell cycle is a critical cellular process and cell cycle arrest during the G<sub>1</sub> phase is a characteristic exhibited by senescent cells. Our results demonstrated that treatment with 25 &#x003BC;M H<sub>2</sub>O<sub>2</sub> arrested HUVECs in the G<sub>0</sub>/G<sub>1</sub> phase as the proportion of cells in the G<sub>0</sub>/G<sub>1</sub> phase was ~70.2&#x00025; compared to 54.4&#x00025; in the control group. NaHS (60 &#x003BC;M) pretreatment eliminated the effects of H<sub>2</sub>O<sub>2</sub> and reduced the proportion of cells in the G<sub>0</sub>/G<sub>1</sub> phase to 58.1&#x00025; (<xref rid="tI-mmr-07-06-1865" ref-type="table">Table I</xref>). These results indicate that H<sub>2</sub>S protects against HUVEC senescence.</p></sec>
<sec>
<title>H<sub>2</sub>S enhances the activation of SIRT1</title>
<p>To determine whether H<sub>2</sub>S regulates HUVEC senescence through a SIRT1-mediated pathway, we examined the expression and activity of SIRT1. Immunoblot analyses indicated that SIRT1 levels were decreased in the H<sub>2</sub>O<sub>2</sub> (25 &#x003BC;M) treatment group compared to the control, and NaHS (60 &#x003BC;M) treatment did not rescue SIRT1 expression (<xref rid="f3-mmr-07-06-1865" ref-type="fig">Fig. 3A and B</xref>). In contrast to its effect on protein expression, NaHS enhanced SIRT1 deacetylase activity <italic>in vitro</italic> (<xref rid="f3-mmr-07-06-1865" ref-type="fig">Fig. 3C</xref>), indicating a direct effect on SIRT1-mediated pathways. These results suggest that NaHS blocks senescence, cell differentiation and stress-induced apoptosis, and promotes cell growth by increasing SIRT1 deacetylase activity.</p></sec>
<sec>
<title>Inhibition of SIRT1 by NAM attenuates the anti-senescent effects of H<sub>2</sub>S</title>
<p>To elucidate the role of SIRT1, HUVECs were pretreated with NaHS and/or NAM, a selective SIRT1 inhibitor, for 48 h prior to treatment with H<sub>2</sub>O<sub>2</sub> (25 &#x003BC;M) for 1 h. NAM attenuated the decrease in SA-&#x003B2;-gal-positive cells inferred by NaHS alone (<xref rid="f2-mmr-07-06-1865" ref-type="fig">Fig. 2A and C</xref>).</p></sec>
<sec>
<title>H<sub>2</sub>S prevents H<sub>2</sub>O<sub>2</sub>-mediated dysfunction in HUVECs</title>
<p>Since cell cycle arrest is a common hallmark of cellular senescence, we examined cell proliferation using the MTT assay. Our study indicated that NaHS (60 &#x003BC;M) improved H<sub>2</sub>O<sub>2</sub>-induced decreases in HUVEC proliferation. This reduction in proliferation was similar, but not significant, in cells pretreated with NAM and NaHS. Treatment with NaHS alone, however, was effective at rescuing the anti-proliferative effects of H<sub>2</sub>O<sub>2</sub> (<xref rid="f4-mmr-07-06-1865" ref-type="fig">Fig. 4A</xref>). To further examine whether H<sub>2</sub>S attenuates senescence-induced endothelial cell dysfunction, we monitored cell migration using a scratch assay (<xref rid="b25-mmr-07-06-1865" ref-type="bibr">25</xref>). Cell migration was significantly reduced by H<sub>2</sub>O<sub>2</sub> and pretreatment with NaHS eliminates this decrease. However, pretreatment with NAM and NaHS was associated with significantly decreased cell migration, which is similar to that observed in cells treated with H<sub>2</sub>O<sub>2</sub> (<xref rid="f4-mmr-07-06-1865" ref-type="fig">Fig. 4C</xref>). We conclude that H<sub>2</sub>S prevents the reduction in cell migration associated with senescence, an effect that is prevented by NAM. These results indicate that H<sub>2</sub>S protects HUVECs against senescence through SIRT1.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>A number of studies have suggested that aging is an independent risk factor for the development of cardiovascular diseases. Previous studies further demonstrated that cellular senescence is involved in various pathological conditions, which are not limited to the cardiovascular system (<xref rid="b26-mmr-07-06-1865" ref-type="bibr">26</xref>). Cellular senescence is a process by which cells irreversibly exit the cell cycle and cease to divide in response to a variety of stresses, including those observed during oxidative states (<xref rid="b27-mmr-07-06-1865" ref-type="bibr">27</xref>). In this study, we established an H<sub>2</sub>O<sub>2</sub>-induced senescent model <italic>in vitro</italic> using HUVECs to investigate the protective role of H<sub>2</sub>S in cell senescence.</p>
<p>Results of the present study demonstrated that a dose of 25 &#x003BC;M H<sub>2</sub>O<sub>2</sub> increased the number of SA-&#x003B2;-gal-positive cells, which was eliminated following treatment with the H<sub>2</sub>S donor, NaHS. These results demonstrated the importance of H<sub>2</sub>S in preventing HUVEC senescence. The results obtained during cell cycle analyses were consistent with this observation. Coincidently, previous studies have shown that H<sub>2</sub>S increases the lifespan in <italic>C. elegans</italic>(<xref rid="b16-mmr-07-06-1865" ref-type="bibr">16</xref>). Our results suggest that H<sub>2</sub>S may be responsible for retarding the aging process. Furthermore, we explored the mechanism of H<sub>2</sub>S against HUVEC senescence.</p>
<p>The results of our study indicated that SIRT1 expression was unchanged after HUVECs were pretreated with 60 &#x003BC;M NaHS for 48 h, while SIRT1 enzyme activity was enhanced, indicating that SIRT1 is a key sensor system for regulating endothelial cell survival, proliferation and senescence. A recent study suggested that SIRT1 overexpression in a mouse model led to a significant improvement in animal health during aging (<xref rid="b28-mmr-07-06-1865" ref-type="bibr">28</xref>). Another study demonstrated that the protective effects of SIRT1 may be due to the regulation of acetylation/deacetylation of key proteins (<xref rid="b29-mmr-07-06-1865" ref-type="bibr">29</xref>). One study indicated that SIRT1 protein levels decrease rapidly with each increase in cell passage and this leads to premature senescence (<xref rid="b30-mmr-07-06-1865" ref-type="bibr">30</xref>). SIRT1 protein stability may play a role in the progressive loss of SIRT1 associated with aging; however, the mechanisms remain elusive. One study indicated that post-translational modification by sumoylation affects the activity of SIRT1 (<xref rid="b31-mmr-07-06-1865" ref-type="bibr">31</xref>). Another study demonstrated that ~10&#x02013;25&#x00025; of liver proteins, including actin, tubulin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), undergo sulfhydration under physiological conditions. Sulfhydration appears to be a physiological post-translational modification for proteins (<xref rid="b32-mmr-07-06-1865" ref-type="bibr">32</xref>). We consider that H<sub>2</sub>S may activate SIRT1 via sulfhydration of the SIRT1 protein. It is possible that SIRT1 is indirectly activated via other H<sub>2</sub>S-induced physiological alterations. The hypothesis that H<sub>2</sub>S shifts redox homeostasis, thereby increasing available NAD<sup>&#x0002B;</sup> (or the NAD<sup>&#x0002B;</sup>/NADH ratio) and resulting in increased SIRT1 activity is controversial.</p>
<p>HUVEC senescence and the consequent reduction of their proliferative and migration ability may contribute to miopragia associated with advanced age. In the present study, we observed that HUVECs treated with 25 &#x003BC;M H<sub>2</sub>O<sub>2</sub> have a reduced ability to migrate, while NaHS treatment prevented this process. However, the mechanisms by which H<sub>2</sub>S improves cell proliferation remain unclear. It is accepted that increased cellular senescence is associated with decreased cell proliferation <italic>in vivo</italic> since senescent cells are not able to divide (<xref rid="b33-mmr-07-06-1865" ref-type="bibr">33</xref>). Therefore, it may be concluded that NaHS (60 &#x003BC;mol/l) improves HUVEC proliferation by delaying cell senescence.</p>
<p>Exogenous H<sub>2</sub>S has notable effects on mammalian physiology that improve survival in changing environmental conditions (<xref rid="b17-mmr-07-06-1865" ref-type="bibr">17</xref>). Despite the molecular mechanisms involved in the modulation of SIRT1 activity, H<sub>2</sub>S affects SIRT1 activity and attenuates senescence, thus establishing that H<sub>2</sub>S exhibits novel endothelial protective effects. FoxO1, is a downstream target of SIRT1, which has been shown to modulate G<sub>1</sub>-S and G<sub>2</sub>-M phase transition by coordinating the expression of multiple important cell cycle regulators (<xref rid="b34-mmr-07-06-1865" ref-type="bibr">34</xref>). In future studies, we aim to evaluate the effect of H<sub>2</sub>S on FoxO1 via SIRT1 expression and activity.</p>
<p>A previous study indicated that H<sub>2</sub>S-releasing diclofenac derivatives, a novel class of non-steroidal anti-inflammatory drugs (NSAIDs), may be of clinical value in the treatment of osteolytic bone disease (<xref rid="b35-mmr-07-06-1865" ref-type="bibr">35</xref>). In addition, preclinical studies have indicated that the novel hydrogen sulfide-modulating agent, S-propargyl-L-cysteine (SPRC) is a potent cardioprotective candidate (<xref rid="b36-mmr-07-06-1865" ref-type="bibr">36</xref>). Our study provides a novel therapeutic role for H<sub>2</sub>S, which protects against HUVEC senescence.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by grants from the National Natural Science Foundation of China (81170277, ZS Jiang), the Special Research Fund for the Doctoral Program of Higher Education of China Project (20124324110003, ZS Jiang) and the Aid Program for Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province.</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">H<sub>2</sub>S</term>
<def>
<p>hydrogen sulfide</p></def></def-item>
<def-item>
<term id="G2">SIPS</term>
<def>
<p>stress-induced premature senescence</p></def></def-item>
<def-item>
<term id="G3">CSE</term>
<def>
<p>cystathionine &#x003B3;-lyase</p></def></def-item></def-list></glossary>
<ref-list>
<title>References</title>
<ref id="b1-mmr-07-06-1865"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sniderman</surname><given-names>AD</given-names></name><name><surname>Furberg</surname><given-names>CD</given-names></name></person-group><article-title>Age as a modifiable risk factor for cardiovascular disease</article-title><source>Lancet</source><volume>371</volume><fpage>1547</fpage><lpage>1549</lpage><year>2008</year></element-citation></ref>
<ref id="b2-mmr-07-06-1865"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrendt</surname><given-names>D</given-names></name><name><surname>Ganz</surname><given-names>P</given-names></name></person-group><article-title>Endothelial function. From vascular biology to clinical applications</article-title><source>Am J Cardiol</source><volume>90</volume><fpage>40L</fpage><lpage>48L</lpage><year>2002</year></element-citation></ref>
<ref id="b3-mmr-07-06-1865"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minamino</surname><given-names>T</given-names></name><name><surname>Miyauchi</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><etal/></person-group><article-title>Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction</article-title><source>Circulation</source><volume>105</volume><fpage>1541</fpage><lpage>1544</lpage><year>2002</year></element-citation></ref>
<ref id="b4-mmr-07-06-1865"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>AL</given-names></name><name><surname>Andr&#x000E9;s</surname><given-names>V</given-names></name></person-group><article-title>Telomeres and cardiovascular disease: does size matter?</article-title><source>Circ Res</source><volume>94</volume><fpage>575</fpage><lpage>584</lpage><year>2004</year></element-citation></ref>
<ref id="b5-mmr-07-06-1865"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorbunova</surname><given-names>V</given-names></name><name><surname>Seluanov</surname><given-names>A</given-names></name><name><surname>Pereira-Smith</surname><given-names>OM</given-names></name></person-group><article-title>Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis</article-title><source>J Biol Chem</source><volume>277</volume><fpage>38540</fpage><lpage>38549</lpage><year>2002</year></element-citation></ref>
<ref id="b6-mmr-07-06-1865"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frippiat</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>QM</given-names></name><name><surname>Zdanov</surname><given-names>S</given-names></name><name><surname>Magalhaes</surname><given-names>JP</given-names></name><name><surname>Remacle</surname><given-names>J</given-names></name><name><surname>Toussaint</surname><given-names>O</given-names></name></person-group><article-title>Subcytotoxic H2O2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts</article-title><source>J Biol Chem</source><volume>276</volume><fpage>2531</fpage><lpage>2537</lpage><year>2001</year></element-citation></ref>
<ref id="b7-mmr-07-06-1865"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimondi</surname><given-names>E</given-names></name><name><surname>di Iasio</surname><given-names>MG</given-names></name><name><surname>Gonelli</surname><given-names>A</given-names></name><name><surname>Celeghini</surname><given-names>C</given-names></name><name><surname>Secchiero</surname><given-names>P</given-names></name><name><surname>Zauli</surname><given-names>G</given-names></name></person-group><article-title>Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells</article-title><source>Invest New Drugs</source><volume>30</volume><fpage>1731</fpage><lpage>1735</lpage><year>2011</year></element-citation></ref>
<ref id="b8-mmr-07-06-1865"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavu</surname><given-names>M</given-names></name><name><surname>Bhushan</surname><given-names>S</given-names></name><name><surname>Lefer</surname><given-names>DJ</given-names></name></person-group><article-title>Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential</article-title><source>Clin Sci (Lond)</source><volume>120</volume><fpage>219</fpage><lpage>229</lpage><year>2011</year></element-citation></ref>
<ref id="b9-mmr-07-06-1865"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Predmore</surname><given-names>BL</given-names></name><name><surname>Lefer</surname><given-names>DJ</given-names></name></person-group><article-title>Hydrogen sulfide-mediated myocardial pre- and post-conditioning</article-title><source>Expert Rev Clin Pharmacol</source><volume>4</volume><fpage>83</fpage><lpage>96</lpage><year>2011</year></element-citation></ref>
<ref id="b10-mmr-07-06-1865"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteman</surname><given-names>M</given-names></name><name><surname>Gooding</surname><given-names>KM</given-names></name><name><surname>Whatmore</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide</article-title><source>Diabetologia</source><volume>53</volume><fpage>1722</fpage><lpage>1726</lpage><year>2010</year></element-citation></ref>
<ref id="b11-mmr-07-06-1865"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzaffar</surname><given-names>S</given-names></name><name><surname>Jeremy</surname><given-names>JY</given-names></name><name><surname>Sparatore</surname><given-names>A</given-names></name><name><surname>Del Soldato</surname><given-names>P</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><name><surname>Shukla</surname><given-names>N</given-names></name></person-group><article-title>H<sub>2</sub>S-donating sildenafil (ACS6) inhibits superoxide formation and gp91phox expression in arterial endothelial cells: role of protein kinases A and G</article-title><source>Br J Pharmacol</source><volume>155</volume><fpage>984</fpage><lpage>994</lpage><year>2008</year></element-citation></ref>
<ref id="b12-mmr-07-06-1865"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeney</surname><given-names>V</given-names></name><name><surname>Kom&#x000F3;di</surname><given-names>E</given-names></name><name><surname>Nagy</surname><given-names>E</given-names></name><etal/></person-group><article-title>Suppression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H(2)S)</article-title><source>Free Radic Biol Med</source><volume>46</volume><fpage>616</fpage><lpage>623</lpage><year>2009</year></element-citation></ref>
<ref id="b13-mmr-07-06-1865"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name></person-group><article-title>Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol</article-title><source>Biochem Biophys Res Commun</source><volume>318</volume><fpage>756</fpage><lpage>763</lpage><year>2004</year></element-citation></ref>
<ref id="b14-mmr-07-06-1865"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteman</surname><given-names>M</given-names></name><name><surname>Cheung</surname><given-names>NS</given-names></name><name><surname>Zhu</surname><given-names>YZ</given-names></name><etal/></person-group><article-title>Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain?</article-title><source>Biochem Biophys Res Commun</source><volume>326</volume><fpage>794</fpage><lpage>798</lpage><year>2005</year></element-citation></ref>
<ref id="b15-mmr-07-06-1865"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Geng</surname><given-names>B</given-names></name></person-group><article-title>Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator</article-title><source>Biochem Biophys Res Commun</source><volume>380</volume><fpage>153</fpage><lpage>159</lpage><year>2009</year></element-citation></ref>
<ref id="b16-mmr-07-06-1865"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DL</given-names></name><name><surname>Roth</surname><given-names>MB</given-names></name></person-group><article-title>Hydrogen sulfide increases thermotolerance and lifespan in <italic>Caenorhabditis elegans</italic></article-title><source>Proc Natl Acad Sci USA</source><volume>104</volume><fpage>20618</fpage><lpage>20622</lpage><year>2007</year></element-citation></ref>
<ref id="b17-mmr-07-06-1865"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Nikolaev</surname><given-names>AY</given-names></name><name><surname>Imai</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Shiloh</surname><given-names>A</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name></person-group><article-title>Negative control of p53 by Sir2alpha promotes cell survival under stress</article-title><source>Cell</source><volume>107</volume><fpage>137</fpage><lpage>148</lpage><year>2001</year></element-citation></ref>
<ref id="b18-mmr-07-06-1865"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Sweeney</surname><given-names>LB</given-names></name><name><surname>Sturgill</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase</article-title><source>Science</source><volume>303</volume><fpage>2011</fpage><lpage>2015</lpage><year>2004</year></element-citation></ref>
<ref id="b19-mmr-07-06-1865"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>H</given-names></name><name><surname>Tokunaga</surname><given-names>E</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells</article-title><source>Oncogene</source><volume>25</volume><fpage>176</fpage><lpage>185</lpage><year>2006</year></element-citation></ref>
<ref id="b20-mmr-07-06-1865"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimri</surname><given-names>GP</given-names></name><name><surname>Lee</surname><given-names>X</given-names></name><name><surname>Basile</surname><given-names>G</given-names></name><name><surname>Acosta</surname><given-names>M</given-names></name><etal/></person-group><article-title>A biomarker that identifies senescent human cells in culture and in aging skin in vivo</article-title><source>Proc Natl Acad Sci USA</source><volume>92</volume><fpage>9363</fpage><lpage>9367</lpage><year>1995</year></element-citation></ref>
<ref id="b21-mmr-07-06-1865"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000F6;se</surname><given-names>GT</given-names></name><name><surname>Korkusuz</surname><given-names>F</given-names></name><name><surname>Ozkul</surname><given-names>A</given-names></name><name><surname>Soysal</surname><given-names>Y</given-names></name><name><surname>Ozdemir</surname><given-names>T</given-names></name><name><surname>Yildiz</surname><given-names>C</given-names></name><name><surname>Hasirci</surname><given-names>V</given-names></name></person-group><article-title>Tissue engineered cartilage on collagen and PHBV matrices</article-title><source>Biomaterials</source><volume>26</volume><fpage>5187</fpage><lpage>5197</lpage><year>2005</year></element-citation></ref>
<ref id="b22-mmr-07-06-1865"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oeseburg</surname><given-names>H</given-names></name><name><surname>Iusuf</surname><given-names>D</given-names></name><name><surname>van der Harst</surname><given-names>P</given-names></name><name><surname>van Gilst</surname><given-names>WH</given-names></name><name><surname>Henning</surname><given-names>RH</given-names></name><name><surname>Roks</surname><given-names>AJ</given-names></name></person-group><article-title>Bradykinin protects against oxidative stress-induced endothelial cell senescence</article-title><source>Hypertension</source><volume>53</volume><fpage>417</fpage><lpage>422</lpage><year>2009</year></element-citation></ref>
<ref id="b23-mmr-07-06-1865"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>DA</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>CDK2 translational down-regulation during endothelial senescence</article-title><source>Exp Cell Res</source><volume>307</volume><fpage>118</fpage><lpage>130</lpage><year>2005</year></element-citation></ref>
<ref id="b24-mmr-07-06-1865"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okatani</surname><given-names>Y</given-names></name><name><surname>Wakatsuki</surname><given-names>A</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name></person-group><article-title>Protective effect of melatonin against homocysteine-induced vasoconstriction of human umbilical artery</article-title><source>Biochem Biophys Res Commun</source><volume>277</volume><fpage>470</fpage><lpage>475</lpage><year>2000</year></element-citation></ref>
<ref id="b25-mmr-07-06-1865"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>CC</given-names></name><name><surname>Park</surname><given-names>AY</given-names></name><name><surname>Guan</surname><given-names>JL</given-names></name></person-group><article-title>In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro</article-title><source>Nat Protoc</source><volume>2</volume><fpage>329</fpage><lpage>333</lpage><year>2007</year></element-citation></ref>
<ref id="b26-mmr-07-06-1865"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakatta</surname><given-names>EG</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name></person-group><article-title>Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a &#x02018;set up&#x02019; for vascular disease</article-title><source>Circulation</source><volume>107</volume><fpage>139</fpage><lpage>146</lpage><year>2003</year></element-citation></ref>
<ref id="b27-mmr-07-06-1865"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Porath</surname><given-names>I</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The signals and pathways activating cellular senescence</article-title><source>Int J Biochem Cell Biol</source><volume>37</volume><fpage>961</fpage><lpage>976</lpage><year>2005</year></element-citation></ref>
<ref id="b28-mmr-07-06-1865"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herranz</surname><given-names>D</given-names></name><name><surname>Mu&#x000F1;oz-Martin</surname><given-names>M</given-names></name><name><surname>Ca&#x000F1;amero</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer</article-title><source>Nat Commun</source><volume>1</volume><fpage>3</fpage><year>2010</year></element-citation></ref>
<ref id="b29-mmr-07-06-1865"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>MY</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><etal/></person-group><article-title>SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells</article-title><source>Circ Res</source><volume>106</volume><fpage>1384</fpage><lpage>1393</lpage><year>2010</year></element-citation></ref>
<ref id="b30-mmr-07-06-1865"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Maier</surname><given-names>B</given-names></name><name><surname>Bartke</surname><given-names>A</given-names></name><name><surname>Scrable</surname><given-names>H</given-names></name></person-group><article-title>Progressive loss of SIRT1 with cell cycle withdrawal</article-title><source>Aging Cell</source><volume>5</volume><fpage>413</fpage><lpage>422</lpage><year>2006</year></element-citation></ref>
<ref id="b31-mmr-07-06-1865"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Olashaw</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Nicosia</surname><given-names>SV</given-names></name><name><surname>Bhalla</surname><given-names>K</given-names></name><name><surname>Bai</surname><given-names>W</given-names></name></person-group><article-title>SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress</article-title><source>Nat Cell Biol</source><volume>9</volume><fpage>1253</fpage><lpage>1262</lpage><year>2007</year></element-citation></ref>
<ref id="b32-mmr-07-06-1865"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mustafa</surname><given-names>AK</given-names></name><name><surname>Gadalla</surname><given-names>MM</given-names></name><name><surname>Sen</surname><given-names>N</given-names></name><etal/></person-group><article-title>H<sub>2</sub>S signals through protein S-sulfhydration</article-title><source>Sci Signal</source><volume>2</volume><fpage>ra72</fpage><year>2009</year></element-citation></ref>
<ref id="b33-mmr-07-06-1865"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>HS</given-names></name></person-group><article-title>Hydrogen sulfide&#x02019;s involvement in modulating nociception</article-title><source>Pain Physician</source><volume>12</volume><fpage>901</fpage><lpage>910</lpage><year>2009</year></element-citation></ref>
<ref id="b34-mmr-07-06-1865"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>KK</given-names></name><name><surname>Myatt</surname><given-names>SS</given-names></name><name><surname>Lam</surname><given-names>EW</given-names></name></person-group><article-title>Many forks in the path: cycling with FoxO</article-title><source>Oncogene</source><volume>27</volume><fpage>2300</fpage><lpage>2311</lpage><year>2008</year></element-citation></ref>
<ref id="b35-mmr-07-06-1865"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frantzias</surname><given-names>J</given-names></name><name><surname>Logan</surname><given-names>JG</given-names></name><name><surname>Mollat</surname><given-names>P</given-names></name><name><surname>Sparatore</surname><given-names>A</given-names></name><name><surname>Del Soldato</surname><given-names>P</given-names></name><name><surname>Ralston</surname><given-names>SH</given-names></name><name><surname>Idris</surname><given-names>AI</given-names></name></person-group><article-title>Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo</article-title><source>Br J Pharmacol</source><volume>165</volume><fpage>1914</fpage><lpage>1925</lpage><year>2012</year></element-citation></ref>
<ref id="b36-mmr-07-06-1865"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name></person-group><article-title>Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs</article-title><source>Xenobiotica</source><volume>42</volume><fpage>304</fpage><lpage>309</lpage><year>2012</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-mmr-07-06-1865" position="float">
<label>Figure 1</label>
<caption>
<p>Low dose H<sub>2</sub>O<sub>2</sub> induces senescence in human umbilical vein endothelial cells (HUVECs). (A) Senescence-associated &#x003B2;-galactosidase (SA-&#x003B2;-gal)-positive HUVECs increased significantly following treatment with 25 &#x003BC;M H<sub>2</sub>O<sub>2</sub>. (B) p21 protein levels in HUVECs following H<sub>2</sub>O<sub>2</sub> treatment. Bars represent mean &#x000B1; standard deviation (SD; <sup>&#x0002A;</sup>P&lt;0.05 vs. control; n&#x0003D;3 experiments). (C) The effect of H<sub>2</sub>O<sub>2</sub> on the cell cycle of HUVECs was arrested. <sup>&#x0002A;</sup>P&lt;0.05 vs. control.</p></caption>
<graphic xlink:href="MMR-07-06-1865-g00.gif"/></fig>
<fig id="f2-mmr-07-06-1865" position="float">
<label>Figure 2</label>
<caption>
<p>NaHS protects human umbilical vein endothelial cells (HUVECs) from senescence. (A) Images of senescence-associated &#x003B2;-galactosidase (SA-&#x003B2;-gal)-stained HUVECs are shown. Combinations of various doses of NaHS and/or nicotinamide (NAM) were administered 48 h prior to H<sub>2</sub>O<sub>2</sub>-induced senescence. (B and C) The number of SA-&#x003B2;-gal-positive cells per microscopic field 3 days following treatment. Values are presented as mean &#x000B1; standard error of the mean (SEM) from three independent experiments. <sup>&#x0002A;</sup>P&lt;0.05 vs. control; <sup>&#x00023;</sup>P&lt;0.05 vs. H<sub>2</sub>O<sub>2</sub> group.</p></caption>
<graphic xlink:href="MMR-07-06-1865-g01.gif"/></fig>
<fig id="f3-mmr-07-06-1865" position="float">
<label>Figure 3</label>
<caption>
<p>H<sub>2</sub>S promotes sirtuin-1 (SIRT1) activity in human umbilical vein endothelial cells (HUVECs). SIRT1 expression was determined after combinations of NaHS (60 &#x003BC;M), nicotinamide (NAM; 5 mM) and NaHS were applied as a pretreatment 48 h prior to H<sub>2</sub>O<sub>2</sub> administration in HUVECs. (A) SIRT1 expression in normal and senescent HUVECs. (B) SIRT1 protein expression was reduced in senescent HUVECs and treatment with NaHS did not attenuate this reduction. (C) SIRT1 deacetylase activity was reduced in the H<sub>2</sub>O<sub>2</sub> treatment group and the addition of NaHS (60 &#x003BC;M) returned the activity to control levels. <sup>&#x0002A;</sup>P&lt;0.05, <sup>&#x00023;</sup>P&lt;0.01 vs. control.</p></caption>
<graphic xlink:href="MMR-07-06-1865-g02.gif"/></fig>
<fig id="f4-mmr-07-06-1865" position="float">
<label>Figure 4</label>
<caption>
<p>H<sub>2</sub>S prevents H<sub>2</sub>O<sub>2</sub>-induced human umbilical vein endothelial cell (HUVEC) dysfunction. (A) Effects on cell proliferation were examined using the MTT assay and cell proliferation was calculated as the percentage of the controls (n&#x0003D;3); <sup>&#x0002A;</sup>P&lt;0.05 vs. control. (B) Representative images showing the scratch at 24 h with various treatments. A mark was placed to locate the same area on the scratch. Images were obtained using an inverted microscope and the open area was calculated. (C) The migration width in different groups was calculated 24 h after treatment. Bars represent migration width in micrometers 24 h following scratching &#x000B1; standard error of the mean (SEM; n&#x0003D;5 experiments); <sup>&#x0002A;</sup>P&lt;0.05 vs. H<sub>2</sub>O<sub>2</sub> group. The NaHS (60 &#x003BC;M) group had a higher migration rate compared to the controls.</p></caption>
<graphic xlink:href="MMR-07-06-1865-g03.gif"/></fig>
<table-wrap id="tI-mmr-07-06-1865" position="float">
<label>Table I</label>
<caption>
<p>Effect of H<sub>2</sub>S on cell cycle arrest of HUVECs induced by 25 &#x003BC;M H<sub>2</sub>O<sub>2</sub>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Group</th>
<th align="center" valign="bottom">G<sub>0</sub>/G<sub>1</sub> (&#x00025;)</th>
<th align="center" valign="bottom">S (&#x00025;)</th>
<th align="center" valign="bottom">G<sub>2</sub>/M (&#x00025;)</th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Control</td>
<td align="center" valign="top">54.41&#x000B1;5.83</td>
<td align="center" valign="top">31.83&#x000B1;3.26</td>
<td align="center" valign="top">13.76&#x000B1;1.85</td></tr>
<tr>
<td align="left" valign="top">H<sub>2</sub>O<sub>2</sub></td>
<td align="center" valign="top">70.24&#x000B1;6.31<xref rid="tfn1-mmr-07-06-1865" ref-type="table-fn">a</xref></td>
<td align="center" valign="top">18.21&#x000B1;2.11</td>
<td align="center" valign="top">11.55&#x000B1;1.23</td></tr>
<tr>
<td align="left" valign="top">NaHS</td>
<td align="center" valign="top">58.16&#x000B1;5.34</td>
<td align="center" valign="top">29.08&#x000B1;2.52</td>
<td align="center" valign="top">12.91&#x000B1;1.36</td></tr>
<tr>
<td align="left" valign="top">H<sub>2</sub>O<sub>2</sub>&#x0002B;NaHS</td>
<td align="center" valign="top">53.72&#x000B1;5.12<xref rid="tfn2-mmr-07-06-1865" ref-type="table-fn">b</xref></td>
<td align="center" valign="top">32.14&#x000B1;3.43</td>
<td align="center" valign="top">14.14&#x000B1;1.69</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-mmr-07-06-1865">
<label>a</label>
<p>P&lt;0.05 vs. control group;</p></fn><fn id="tfn2-mmr-07-06-1865">
<label>b</label>
<p>P&lt;0.05 vs. H<sub>2</sub>O<sub>2</sub> group (n&#x0003D;3).</p></fn><fn id="tfn3-mmr-07-06-1865">
<p>HUVECs, human umblical vein endothelial cells.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
